GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevena Inc (NAS:TRVN) » Definitions » Insider Ownership

Trevena (Trevena) Insider Ownership : 12.10 % (As of Apr. 30, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Trevena Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Trevena's insider ownership is 12.10%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Trevena's Institutional Ownership is 1.26%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Trevena's Float Percentage Of Total Shares Outstanding is 98.89%.

Trevena Insider Ownership Historical Data

The historical data trend for Trevena's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trevena Insider Ownership Chart

Trevena Historical Data

The historical data trend for Trevena can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Insider Ownership 10.31 10.31 8.25 8.25 8.25 7.45 12.82 12.82 12.10 12.10

Trevena Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Trevena (Trevena) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevena Inc (NAS:TRVN) » Definitions » Insider Ownership
Comparable Companies
IBIO ERNA KTTA CYCC APM LIPO CING BTAX BPTH TOVX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
6T40:Germany
Address
955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA, USA, 19087
Website
https://www.trevena.com
Trevena Inc is an American biopharmaceutical company focused on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders.
Executives
Mark Corrigan director
Mark Demitrack officer: SVP, Chief Medical Officer 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Robert T Yoder officer: SVP, Chief Business Officer 955 CHESTERBROOK BOULEVARD, SUITE 110, SUITE 200, CHESTERBROOK PA 19087
Carrie L. Bourdow director, officer: President & CEO C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Patricia M. Drake officer: SVP, Chief Commercial Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Barry Shin officer: SVP, CFO C/O TREVENA, INC., 955 CHESTERBROOK BLVD, SUITE 110, CHESTERBROOK PA 19087
Marvin Johnson director C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Moulder Leon O Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Jason Raleigh Nunn director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Scott Applebaum officer: CLCO; SVP, Regulatory Affairs C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
John P. Hamill officer: Int. Prin. Fin. Off. and PAO 4092 NEW HOPE ROAD, FURLONG PA 18925